Infectious agents and different course of multiple sclerosis: a systematic review

Acta Neurologica Belgica

Volumn 118, Issue 3, 2018, Pages 361-377

  Saberi, Alia ^a   Akhondzadeh, Shahin ^b   Kazemi, Samaneh ^c  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Infection; Multiple sclerosis; Progressive; Relapsing remitting

Indexed keywords

BETA INTERFERON; CHEMOKINE RECEPTOR CCR2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; MEMBRANE COFACTOR PROTEIN; TUMOR NECROSIS FACTOR;

ANTIBODY TITER; CELL PROLIFERATION; CHLAMYDIA PNEUMONIAE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTIOUS AGENT; MULTIPLE SCLEROSIS; NESTED POLYMERASE CHAIN REACTION; NONHUMAN; POLYMERASE CHAIN REACTION; RELAPSE; REVIEW; SYSTEMATIC REVIEW; TORQUE TENO VIRUS 1; VARICELLA ZOSTER VIRUS; COMPLICATION; INFECTION; MICROBIOLOGY; PATHOGENICITY;

CHLAMYDOPHILA PNEUMONIAE; DISEASE PROGRESSION; HERPESVIRUS 6, HUMAN; HUMANS; INFECTION; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TORQUE TENO VIRUS;

EID: 85049825565     PISSN: 03009009     EISSN: 22402993     Source Type: Journal    
DOI: 10.1007/s13760-018-0976-y     Document Type: Review

References (94)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH (1992) Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neural 31:333–336
2. Lassmann H, Raine CS, Antel J, Prineas JW (1998) Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86:213–217
3. Gilden DH, Devlin ME, Burgoon MP, Owens GP (1996) The search for virus in multiple sclerosis brain. Mult Scler 2:179–183
4. Farid R, Norasteh A, Hatamian H (2016) The effect of core stability exercise program on the balance of patients with multiple sclerosis. Caspian J Neurol Sci 2(4):9–17
5. Semnani M, Mashayekhi F, Azarnia M, Salehi Z (2016) Effects of green tea epigallocatechin-3-gallate (EGCG) on proteolipid protein (PLP) and oligodendrocyte transcription factor 1 (Olig1) expression in the cerebral cortex of cuprizone induced multiple sclerosis mice; a western blot study. Caspian J Neurol Sci 2(6):1–9
6. Saeidi M, Raftari S, Roudbary S, Rezaeitalab F, Hatamian H (2016) Peripheral neuro electrodiagnostic abnormalities in patients with multiple sclerosis: a cross sectional study. Caspian J Neurol Sci 2(7):41–48
7. Janalipour K, Kafi M, Hatamian H, Rezapour P (2017) The effectiveness of yoga therapy in reducing anxiety, stress and depression in women with multiple sclerosis. Caspian J Neurol Sci 3(10):151–158
8. Amir F, Ahadi H, Nikkhah K, Seirafi M (2017) The effectiveness of acceptance and commitment group therapy and group logotherapy in reducing perceived stress among MS patients. Caspian J Neurol Sci 3(11):175–184
9. Saberi A, Hatamian HR, Nemati SH, Banan R (2012) Hearing statement in multiple sclerosis: a case control study using auditory brainstem responses and otoacoustic emissions. Acta Med Iran 50(10):679–683
10. Saberi A, Roudbary SA, Hatamian HR, Akbari MS, Sedigh-Rahim-Abadi MR (2012) The type of multiple sclerosis when accompanied with seizure: can seizure predict the progression of MS? Akt Neurol 39:1–5. (text in German)
11. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343:938–952
12. Lublin DF, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907–11
13. Etemadifar M, Moeini P, Nabavi S (2017) Fingolimod versus high dose interferon beta-1a in multiple sclerosis: a randomized clinical trial. Caspian J Neurol Sci 3(8):1–8
14. Roudbary S, Yousefzadeh-Chabok S, Behzadnia H, Bakhshayesh-Eghbali B, Emamhadi M, Ghayeghran A et al (2017) Non-adherence to disease-modifying treatments in patients with multiple sclerosis. Caspian J Neurol Sci 3(10):128–134
15. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913–919
16. Etemadifar M, Ghadimi M, Ghadimi K, Alsahebfosoul F (2017) The serum amyloid β level in multiple sclerosis: a case–control study. Caspian J Neurol Sci 3(11):214–221
17. Walvoort MTC, Testa C, Eilam R et al (2016) Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of nontypeable Haemophilus influenzae. Sci Rep 6:39430. 10.1038/srep39430
18. Ashtari F, Saberi A, Shayegannejad V, Khosravi AR, Sherkat R, Khosravi E (2007) Association between Chlamydia pneumoniae infection and carotid atherosclerotic plaques. JRMS 12(4):165–171
19. Ashtari F, Shayghannejad V, Saberi A, Karkheyran F, Khosravi E (2007) Chlamydia pneumonia infection and thrombotic ischemic stroke. J Isfahan Med School 24(83):8–14 [Text in Persian].
20. Ashtari F, Shayegannejad V, Khosravi AR, Alia Saberi A, Niknazar MA (2006) The influence of Chlamydia pneumoniae infection on Intima-Media-thickness (IMT) in common carotid artery. ARYA Atheroscler 2(3):130–133
21. Ashtari F, Shayghannejad V, Saberi A, Rabiei E (2006) Association between Helicobacter pylori infection and carotid atherosclerotic plaque. Iran J Neurol 5(14):8–14
22. Ashtari F, Shayegannejad V, Saberi A, Rabiei E (2008) Relationship between Helicobacter pylori immunoglobulin g antibody and thrombotic ischemic stroke. Acta Medica Iranica 46(4):303–306
23. Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Part II: noninfectious factors. Ann Neurol;61:288–299. Ann Neurol 61:504–513
24. Szczucinski A, Losy J (2006) Infectious agents in the pathogenesis of multiple sclerosis. Przegl Epidemiol 60(Suppl 1):160–165
25. Dighiero G, Rose NR (1999) Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today 20:423–428
26. Banks T, Rouse B (1992) Herpesviruses—immune escape artists? Clin Inf Dis 14:933–941
27. Pormohammad A, Azimi T, Falah F, Faghihloo E (2018) Relationship of human herpes virus 6 and multiple sclerosis: a systematic review and meta-analysis. J Cell Physiol 233(4):2850–2862
28. Swanborg RH, Whittum-Hudson JA, Hudson AP (2003) Infectious agents and multiple sclerosis –are Chlamydia pneumoniae and human herpes virus 6 involved? J Neuroimmunol 136(1–2):1–8
29. Fotheringham J, Jacobson S (2005) Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes 12;4–9
30. Stratton CW, Wheldon DB (2006) Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumonia. Trends Microbiol 14(11):474–479
31. Cook SD (2004) Does Epstein–Barr virus cause multiple sclerosis? Rev Neurol Dis 1:115–123
32. Christensen T (2006) The role of EBV in MS pathogenesis. Int MS J 13:52–57
33. Ordo˜nez G, Pineda B, Garcia-Navarrete R, Sotelo J (2004) Brief presence of varicellazoster viral DNA in mononuclear cells during relapses of multiple sclerosis. Arch Neurol 61:529–532
34. Tarrats R, Ordo˜nez G, Rios C, Sotelo J (2002) Varicella, ephemeral breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans. Acta Neurol Scand 105:88–94
35. Cirino F, Webley WC, West C, Croteau NL, Andrzejewski C Jr, Stuart ES (2006) Detection of Chlamydia in the peripheral blood cells of normal donors using in vitro culture, immunofluorescence microscopy, and flow cytometry techniques. BMC Infect Dis 6:23
36. Jaruvongvanich V, Sanguankeo A, Jaruvongvanich S, Upala S (2016) Association between Helicobacter pylori infection and multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 7:92–97
37. Wang ZY, Hansen K, Sidén A, Cruz M (1993) Intrathecal synthesis of anti-Borrelia burgdorferi antibodies in neuroborreliosis: a study with special emphasis on oligoclonal IgM antibody bands. Scand J Immunol 37:369–376
38. Sherbet G (2009) Bacterial infections and the pathogenesis of autoimmune conditions. Br J Med Pract 2:6–13
39. Ercolini AM, Miller SD (2009) The role of infections in autoimmune disease. Clin Exp Immunol 155:1–15
40. Berger T, Reind M (2015) Antibody biomarkers in CNS demyelinating diseases—a long and winding road. Eur J Neurol 22:1162–1168
41. Levin MC, Lee S, Gardner LA, Shin Y, Douglas JN, Cooper Ch (2013) Autoantibodies to non-myelin antigens as contributors to the pathogenesis of multiple sclerosis. J Clin Cell Immunol. 10.4172/2155-9899.1000148
42. Fraussen J, Claes N, de Bock L, Somers V (2014) Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 13:1126–1137
43. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA et al (2016) STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaborate. BMJ Open 6(11): e012799
44. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377–384
45. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
46. Wuest SC, Mexhitaj I, Chai NR, Romm E, Scheffel J et al (2014) A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS One 9(8):e105434
47. McKay KA, Kwan V, Duggan T, Tremlett H (2015) Risk factors associated with the onset of relapsing–remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 10.1155/2015/817238
48. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H et al (2000) Association between clinical disease activity and Epstein–Barr virus reactivation in MS. Neurology 55(2):178–184
49. Cermelli C, Jacobson S (2000) Viruses and multiple sclerosis. Viral Immunol 13:255–267
50. Villoslada P, Juste C, Tintore M, Llorenç V, Codina G, Pozo-Rosich P et al (2003) The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 60:1944–8
51. Simpson S Jr, Taylor B, Dwyer DE, Taylor J, Blizzard L, Ponsonby AL et al (2012) Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult Scler 18(6):799–806
52. Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, Bartolome M, Garcia-Martinez MA, Arroyo R et al (2011) Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. Eur J Neurol 18(8):1027–1035
53. Behzad-Behbahani A, Mikaeili MH, Entezam M, Mojiri A, Pour GY, Arasteh MM et al (2011) Human herpesvirus-6 viral load and antibody titer in serum samples of patients with multiple sclerosis. J Microbiol Immunol Infect 44(4):247–251
54. Ahram M, El-Omar A, Baho Y, Lubad MA (2009) Association between human herpesvirus 6 and occurrence of multiple sclerosis among Jordanian patients. Acta Neurol Scand 120(6):430–435
55. Koch WC (2001) Fifth (human parvovirus) and sixth (herpesvirus 6) diseases. Curr Opin Infect Dis 14:343–356
56. Nora-Krukle Z, Chapenko S, Logina I, Millers A, Platkajis A, Murovska M (2011) Human herpesvirus 6 and 7 reactivation and disease activity in multiple sclerosis. Medicina (Kaunas) 47(10):527–531
57. Rodríguez-Violante M, Ordoñez G, Bermudez JR, Sotelo J, Corona T (2009) Association of a history of varicella virus infection with multiple sclerosis. Clin Neurol Neurosurg 111(1):54–56
58. Sotelo J, Ordoñez G, Pineda B, Flores J (2014) The participation of varicella zoster virus in relapses of multiple sclerosis. Clin Neurol Neurosurg 119:44–48
59. Ascherio A, Munger KL (2010) Epstein–Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 5:271–277
60. Warner HB, Carp RI (1981) Multiple sclerosis and Epstein–Barr virus. Lancet 2(8258):1290
61. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol 25:587–617
62. Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R et al (2013) B-cell enrichment and Epstein–Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol 72:29–41
63. Correale J, Gaitán MI, Ysrraelit MC, Fiol MP (2017) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 140(3):527–546
64. Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A et al (2008) Strong EBV-specific CD8 + T-cell response in patients with early multiple sclerosis. Brain 131(Pt 7):1712–1721
65. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2004) Acute infection with Epstein–Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 78(10):5194–5204
66. van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geutskens SB, van Noort JM (1999) EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 162:129–135
67. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A et al (1995) Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing–remitting multiple sclerosis is associated with disease activity. Ann Neurol 37(1):82–88
68. Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thompson AJ et al (1997) Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 120(Pt 1):1–13
69. Ott M, Seidl C, Westhoff U, Stecker K, Seifried E, Fischer PA et al (1998) Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tissue Antigens 51(3):301–304
70. Fujinami RS, Oldstone MB (1985) Amino acid homology between the encephalolitogenic site of myelin basic protein and virus: mechanisms for autoimmunity. Science 230:1043–1045
71. Wucherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695–705
72. Hemmer B, Fleckenstein BT, Vergelli M, Jung G, McFarland H, Martin R et al (1997) Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 185:1651–1659
73. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML et al (1995) Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 182(6):1985–1996
74. Colby BM, Shaw JE, Elion GB, Pagano JS (1980) Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein–Barr virus DNA replication. J Virol 34(2):560–568
75. Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous. Disease? Ann Neurol 65:239–248
76. Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J et al (2009) Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73(1):32–38
77. Ramroodi N, Niazi AA, Sanadgol N, Ganjali Z, Sarabandi V (2013) Evaluation of reactive Epstein–Barr virus (EBV) in Iranian patient with different subtypes of multiple sclerosis (MS). Braz J Infect Dis 17(2):156–163
78. Munger KL, Levin LI, O’Reilly EJ, Falk KI, Ascherio A (2011) Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17(10):1185–1193
79. Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A et al (2013) Epstein–barr virus in oral shedding of children with multiple sclerosis. Neurology 81(16):1392–1399
80. Ingram G, Bugert JJ, Loveless S, Robertson NP (2010) Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol 17(11):1386–1389
81. Boelen E, Steinbusch HW, van der Ven AJ, Grauls G, Bruggeman CA, Stassen FR (2007) Chlamydia pneumoniae infection of brain cells: an in vitro study. Neurobiol Aging 28(4):524–532
82. Aghaei M, Ashtari F, Bahar M, Falahian MR (2011) Chlamydia pneumoniae seropositivity in Iranian patients with multiple sclerosis: a pilot study. Neurol Neurochir Pol 45(2):128–131
83. Rindfleisch E (1863) Histologisches detail zu der grauen degeneration von gehirn und ruckenmark. Arch Pathol Anat Physiol 26(5–6):474–483
84. Mattson MP (2004) Infectious agents and age-related neurodegenerative disorders. Ageing Res Rev 3:105–120
85. Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E (2004) Cerebrospinal fluid molecular demonstration of Chlamydia pneumonia DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing/remitting multiple sclerosis. Mult Scler 10(4):360–369
86. Munger KL, Peeling RW, Hernán MA, Chasan-Taber L, Olek MJ, Hankinson SE et al (2003) Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 14(2):141–7
87. Munger KL, DeLorenze GN, Levin LI, Rubertone MV, Vogelman JH, Peck CA et al (2004) A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology 62(10):1799–1803
88. Krametter D, Niederwieser G, Berghold A, Birnbaum G, Strasser-Fuchs S, Hartung HP et al (2001) Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult Scler 7(1):13–18
89. Fainardi E, Castellazzi M, Casetta I, Cultrera R, Vaghi L, Granieri E et al (2004) Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated with a subset of multiple sclerosis patients with progressive forms. J Neurol Sci 217(2):181–188
90. Agostini HT, Ryschkewitsch CF, Baumhefner RW, Tourtellotte WW, Singer EJ, Komoly S et al (2000) Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy. J Neurovirol 6(2):101–108
91. Rasmussena HB, Kellyb MA, Francisc DA, Clausena J (2000) Association between the endogenous retrovirus HRES-1 and multiple sclerosis in the United Kingdom—evidence of genetically different disease subsets? Dis Markers 16(3–4):101–104
92. Chan PK, Tam WH, Yeo W, Cheung JL, Zhong S, Cheng AF (2001) High carriage rate of TT virus in the cervices of pregnant women. Clin Infect Dis 32(9):1376–1377
93. Rocchi J, Ricci V, Albani M, Lanini L, Andreoli E, Macera L et al (2009) Torque teno virus DNA drives proinflammatory cytokines production and secretion by immune cells via toll-like receptor 9. Virology 394(2):235–42
94. Mancuso R, Saresella M, Hernis A, Agostini S, Piancone F, Caputo D et al (2013) Torque teno virus (TTV) in multiple sclerosis patients with different patterns of disease. J Med Virol 85(12):2176–2183